Immungenetics is an ISO 9001 and ISO 13485 certified neuroscience drug development company with maturing assets in the fields of Alzheimer’s, dementia, memory disorders and auto-immune diseases. The company intends to offer a commercial diagnostic screening service for neuro-degenerative and auto-immune diseases across the EU providing ‘companion diagnostics’ with pharmaceutical companies already established in these clinical areas. Immungenetics is running a phase-II clinical trial for Alzheimer's diagnostic and therapy. The company also has an orphan drug designation for Bullous Pemphigoid.
The Immungenetics AG is a specialist neuroscience drug development company with maturing assets in the fields of Alzheimer’s, dementia/memory disorders, and autoimmune diseases. Neurodegenerative diseases are a chronic and growing area of need directly related to the ageing global population for which current therapies often provide only symptomatic relief. Moreover, these diseases account for significant treatment costs. The development of medicines for prevention, treatment and management of neurodegenerative diseases is particularly challenging due to difficulties in determining relevant clinical end points, the ‘moving baseline’ as the human body ‘adapts’ to changes and a strong placebo effect. As a result, the pharmaceutical industry has weak CNS product pipelines.
Immungenetics has access to a large human database which can enable the identification of genes associated with neurodegenerative and autoimmune diseases. The company’s proprietary screening tools enables doctors to select a personalized medication for their patients and can help the pharmaceutical industry find new drug targets through improved knowledge of underlying causes of disease. Both these approaches result in lower costs through either optimized treatment or improved efficiency of new drug discovery and validation.